Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis

American Journal of Clinical Dermatology

Volumn 6, Issue 2, 2005, Pages 65-77

  Breuer, Kristine ^a   Werfel, Thomas ^a   Kapp, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE ACETATE; ITRACONAZOLE; LACTAM DERIVATIVE; MACROLACTAM; PIMECROLIMUS; TACROLIMUS; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ATOPIC DERMATITIS; BURNING SENSATION; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL TRIAL; CREAM; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERYTHEMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; LONG TERM CARE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ABSORPTION; SKIN ATROPHY; SKIN INFECTION; TACHYPHYLAXIS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 17244365003     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506020-00001     Document Type: Review

References (97)

1. Kapp A. Atopic dermatitis: the skin manifestation of atopy. Clin Exp Allergy 1995; 25: 210-9
2. Schultz Larsen F, Thomas T, Svensson A. The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34: 760-4
3. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 1992; 17: 385-91
4. Rajka G. Essential aspects of atopic dermatitis. Berlin: Springer Verlag. 1989
5. Kemp AS. Cost of illness of atopic dermatitis in children: a social perspective. Pharmacoeconomics 2003; 21 (2): 105-13
6. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 143: 514-22
7. Breuer K, Wulf A, Heratizadeh A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004; 34: 817-24
8. Werfel T, Kapp A. Environmental and other major provocation factors in atopic dermatitis. Allergy 1998; 53: 731-9
9. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. Atopy Patch Test Study Group. J Am Acad Dermatol 1999; 40: 187-93
10. Gondo A, Saeki NTY. Challenge reactions in atopic dermatitis after percutaneous entry of mite allergen. Br J Dermatol 1986; 115: 485-93
11. Wistokat-Wuelfing A, Schmidt P, Darsow U. et al. Atopy patch test reactions are associated with T lymphocyte-mediated allergen-specific immune responses in atopic dermatitis. Clin Exp Allergy 1999; 29: 513-21
12. Bruijnzeel PL, Kuijper PH, Kapp A, et al. The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis. Clin Exp Allergy 1993; 23: 97-109
13. Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite-induced patch test site in atopic dermatitis. J Dermatol Sci 1990; 1: 361-8
14. Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (FcεRI). J Exp Med 1992; 175: 1285-90
15. Mudde GC, von Reijsen FC, Boland GJ, et al. Allergen presentation by epidermal Langerhans cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990; 69: 335-41
16. Grewe M, Gyufko K, Schöpf E, et al. Lesional expression of interferon-g in atopic eczema. Lancet 1994; 343: 25-6
17. Thepen T, Langeveld-Wiltschut EG, van Reijsen FC, et al. Bi-phasic response against aeroallergen in atopic dermatitis showing a switch from initial TH2 response into a TH1 response in situ. J Allergy Clin Immunol 1996; 97: 828-37
18. David TJ, Cambridge GC. Bacterial infection and atopic eczema. Arch Dis Child 1986; 81: 20-3
19. Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001; 56: 1034-41
20. Hill CJ, Rosenberg A. Adverse effects from topical corticosteroids. Cutis 1978; 21: 624-48
21. Saurat JH. Systemic side-effects of topical preparation in children. Sem Hop 1982; 58: 1643-9
22. Feiwel M, Kelly WF. Adrenal unresponsiveness associated with clobetasol propionate. Lancet 1974; II: 112-3
23. Goto T, Kino T, Hatanaka H. FK506: historical perspectives. Transplant Proc 1991; 23: 2713-7
24. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000; 9: 69-77
25. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359-72
26. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73
27. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell 1991; 66: 807-15
28. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today 1992; 13: 136-42
29. Mori A, Suko M, Nishizaki Y, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporine A and glucocorticoid. Int Arch Allergy Immunol 1994; 104 Suppl. 1: 32-5
30. de Paulis A, Cirillo R, Ciccarelli A, et al. Characterization of the anti-inflammatory effect of FK506 on human mast cells. J Immunol 1991; 147: 4278-85
31. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99: 723-8
32. Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-80
33. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-25
34. Panhans-Groß A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52
35. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122 (3): 673-84
36. Meingassner JG, Kowalski E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149 (4): 853-7
37. Kino T, Hatanaka H, Hashimoto M. FK506 a novel immunosuppressant isolated from a Streptomyces I: fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-55
38. Pournaras CC, Lübbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol 2001; 116: 480-1
39. Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces the Staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001; 107: 196-7
40. Hauk PJ, Leung DYM. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol 2001; 107: 391-2
41. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27: 29-34
42. Petering H, Kiehl P, Breuer K, et al. Pyoderma gangraenosum: successful topical therapy with tacrolimus (FK506). Hautarzt 2001; 52: 47-50
43. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349-50
44. Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and momethasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46: 73-7
45. Yoshimasu T, Ohtani T, Sakamoto T, et al: Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus. Eur J Dermatol 2002; 12: 50-2
46. Mrowietz U, Graeber M, Bräutigam M, et al. The novel ascomycin derivate SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-6
47. Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35-41
48. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91
49. Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147: 154-6
50. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. Arch Dermatol 2001; 137: 1202-6
51. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003; 9: 13
52. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-7
53. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41
54. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144: 781-7
55. Van Leent EJM, Ebelin ME, Burtin PDB, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204: 63-8
56. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
57. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: 1-8
58. Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876-87
59. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44
60. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-57
61. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46
62. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I efficacy. J Am Acad Dermatol 2001; 44 Suppl. 1: S28-38
63. Ruzicka T, Bieber T, Schoepf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816-21
64. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55
65. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76
66. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-89
67. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentration and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-5
68. McKee M, Segev D, Wise B. Initial experience with FK 506 in pediatric renal transplant recipients. J Pediatr Surg 1997; 32: 688-90
69. Younes BS, McDiarmid SV, Martin MG. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-9
70. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-50
71. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome. Arch Dermatol 1999; 135: 823-32
72. Boralevi F, Buzenet C, Taieb A. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003; 149: 193-227
73. Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133: 492-500
74. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet 1994; 344 (8926): 883
75. Kang S, Lucky A, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64
76. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003; 21 (3): 159-79
77. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life in adults and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-72
78. Van Leent EJM, Graeber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9
79. Luger T, Van Leent EJM, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-94
80. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 138: 495-504
81. Ho V, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62
82. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-7
83. Breuer K, Brautigam M, Kapp M, et al. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004; 209 (4): 314-20
84. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51 (4): 515-25
85. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150 (3): 554-62
86. Breuer K, Werfel T, Kapp A. Pimecrolimus for the treatment of atopic dermatitis. Therapy. In press
87. Reitamo S, Wollenberg A, Schoepf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006
88. Bonifazi E, Garofalo L, Pisani V, et al. Role of some infectious agents in atopic dermatitis. Acta Dermatol Venereol Stockh 1985; 114: 98-100
89. Fleischer AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70
90. Blankenship JR, Steinbach WJ, Perfect JR, et al. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Invest Drugs 2003; 4: 192-9
91. Protopic prescribing information. Deerfield (IL): Fujisawa, 2002
92. Rico MJ, Naylor M, Elmets CA, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer [abstract]. J Eur Acad Dermatol Venerol 2003; 17 Suppl. 1: 53
93. Oikarinen A, Haapasaari KM, Sutinen M, et al. The molecular basis of glucocorti-coid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vitro. Br J Dermatol 1998; 139: 1106-10
94. Hisatomi A, Mitamura T, Kimura M, et al. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal hogeneity in rats. J Toxicol Pathol 1997; 10: 97-102
95. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8
96. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76
97. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13